Friday, April 13
7:30
Coffee (Breakfast
Technology Workshop Sponsorship Available)
8:30
Chairperson’s Opening Remarks
| Featured
presentations:
8:40
Microarrays for Clinical Diagnostics
TBA, Center for Devices
and Radiological Health, US Food and Drug Administration (invited)
9:20
Get Better Results from In-House Printed Oligo Arrays
Tao Han, Ph.D., Staff
Scientist, Center for Functional Genomics, Division of Systems Toxicology,
National Center for Toxicological Research, U.S. Food and Drug Administration
DNA microarrays are the most commonly used tools to study gene
expression profiling in biological research. Many microarray core facilities
have been established throughout the world to lower the overall cost of
microarray application. One of the big challenges for the in-house printed
oligo arrays has been how to generate consistent and reliable data from the
microarray experiments. Our efforts in optimization of hybridization
conditions for in-house printed oligo arrays showed we can generate highly
reproducible and accurate data from in-house printed oligo arrays.
|
10:00 Refreshment
Break in Exhibit Hall
10:45 Statistical
Pathway Analysis of DNA Microarray Data Revealed a Common Molecular Mechanism
of Bone Formation by PTH and GSK3b Inhibitor
Tao Wei, Ph.D., Senior
Research Scientist, Integrative Biology, Eli Lilly and Company
A novel statistical analysis method was developed. By applying
the method to analyze a DNA microarray Dataset, we discovered a common
molecular mechanism of bone formation induced by PTH or Forteo and GSK3b
inhibitor, which was later confirmed experimentally.
11:15 Scanning
Microarrays: Current Challenges
and New Opportunities
Jerilyn A. Timlin,
Ph.D., Senior Member of the Technical Staff, Biomolecular Analysis and Imaging
Department, Sandia National Laboratories
This talk will summarize critical microarray scanning
parameters and discuss their potential affect on expression data quality.
Although the focus will be primarily on two-color, glass substrate
microarray format, general priniciples should be applicable to other array
formats. In addition, promising scanning technolgies of the future will be
highlighted.
11:45 On
the Trail of a Transcription-Based Peripheral Blood Diagnostic for
Discriminating Ulcerative Colitis and Crohn’s Disease
Fred Immermann, Ph.D.,
Associate Director, Translational Medicine Biostatistics, Wyeth Research
Predictive models for discriminating ulcerative colitis from
Crohn’s disease were developed using transcription levels in peripheral
blood samples measured in microarrays. A
second generation of predictive models were constructed using measurements on
the same samples using real-time PCR. Prospective
validation of the models using an independently obtained set of samples has
shown that the underlying concept is sound.
A robust diagnostic will require further refinement of sample
collection, sample processing, and data normalization methods.
12:15 Lunch on Your Own (Luncheon Seminar Sponsorship Available)
1:35
Hands-On Technology Workshops (Sponsorship
Available)
Selected leaders and technology providers in the field will
explain their technology and equipment in detail and the attendees will have
the opportunity for a “close-up-and-personal”
hands on experience. Plenty of time for individual questions will be given.
| Participating
Organizations: |
| |
|
 |
Targeted Cell Isolation for Genomic and Proteomic Applications: Leica
LMD6000
Dr. Christopher Vega, Leica Microsystems
Leica Microsystems presents the LMD6000 Laser MicroDissection system. Cells of interest are easily selected for collection via an intuitive software system that can be enhanced with automated cell detection for the latest in intelligent sample preparation. The powerful diode laser dissects tissue quickly and accurately at magnifications ranging from 4x to 150x. The upright microscope platform of the LMD6000 incorporates a non-contact collection device; where dissected samples can fall directly into the protection of a lysis buffer for isolate samples free of contamination or degradation. Leica’s laser microdissection specialists will be on hand for system demonstrations and application discussions. |
|
 |
Advances in Laser Capture Microdissection and Applications:ArcturusXT and Turbo
Labeling
Dr. Poonam Taneja, Molecular Devices Corp.
- Laser Capture Microdissection and UV Cutting in a single platform
- Open Modular platform and simplified workflow of ArcturusXT
- Ultimate flexibility in sample source and preparation
- Applications
|
|
 |
PALM
MicroBeam: Covergence of Analytical Digital Microscopy and Automated
Microdissection
Oliver Prange, Ph.D., Applications Scientist, Carl Zeiss MicroImaging,
Inc. |
|
3:05
Refreshment Break in Exhibit Hall
3:35
Cell Microarray - The New Generation of Microarray Technology
Sarah Haigh, Ph.D.,
Senior Scientist, R&D, Molecular Cytomics
Microarray technologies have become an indispensable research
tool in the drug discovery field as a method of uncovering novel drug targets
providing large-scale datasets of the expressed genome or proteome in a rapid
and cost effective manner. However, it is becoming clear that these advanced
tools cannot address the complexity of the cellular environment in which DNA,
proteins and millions of small molecules are interacting in a very dynamic
way. The novel living-cell microarray in many ways resembles current
microarray technologies by providing a way to perform cell-based assays on
thousands of individual cells, in a very small area and with minimal reagent.
Here we describe cell array experiments that enable researchers to address
cellular complexity by monitoring responses from thousands of cells at the
resolution of the individual cell, and provides a solution with which to
reveal and analyze the heterogeneity of cell populations.
4:05
Microarray Transcriptional Networks for Reconstruction of Disease
Pathways and Infection Biomarkers
Willy Valdivia-Granda,
CEO, Orion Integrated Biosciences Inc.
While host gene expression microarray profiling can be used to
detect infection, the analysis of this information using unsupervised and
supervised classification techniques can produce contradictory results.Here,
we present a systematic approach to incorporate molecular genome annotation
features that are key for identifying early infection biomarkers (EIB). Our
analysis identified EIBs expressed in peripheral blood mononuclear cells (PBMCs)
collected from humans and cynomolgus macaques infected with different strains
via aerosol and intravenous exposure. The level of expression of these EIBs
was correlated with disease progression and severity. This information was
overlap to protein interaction data reported in public databases.
Our ability to represent multiple gene-centric data sources to discover
significant functional relationships between transcriptomic and proteomic
information allow researchers to rapidly identify biologically meaningful
relationships associated with disease.
4:35
Panel Discussion
4:35 Identification of Genomic Markers that Predict Response to Antileukemic
Therapy
Mitch Raponi, Ph.D., Research Manager, Pharma Biomarker Support Group, Ortho-Clinical Diagnostics, Johnson &
Johnson
The orally available farnesyltransferase inhibitor tipifarnib (ZARNESTRA®) has demonstrated clinical efficacy in hematological disease. In an effort to identify patients with a higher likelihood of response, we have employed microarray technology to identify gene expression markers that predict response to tipifarnib. This presentation will review the identification of molecular predictors of response to tipifarnib from two phase II clinical studies in AML, and how this may impact our appreciation of pathways that are affected by farnesyltransferase inhibition.
5:05
End of Conference
